Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of th
-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH -- -- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying a...
Source: pharmiweb.com